Tempus, Abramson Cancer Center collaborate on immunotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

TEMPUS, a technology company focused on supporting physicians delivering customized cancer care, and the University of Pennsylvania Abramson Cancer Center partnered to better determine which patients will have a positive response to immunotherapy treatment based on next generation genomic and transcriptomic sequencing.

As part of a research collaboration, Tempus will provide sequencing and analysis of de-identified pancreatic and melanoma cancer patient data to Penn. Utilizing next-generation sequencing, machine learning and bioinformatics, Tempus will help physicians analyze these data sets for relevant patterns that can help inform which immunotherapies are most likely to be effective in a given cohort of patients.

“Tempus is committed to bringing relevant information and technology to healthcare providers battling cancer,” said Eric Lefkofsky, co-founder and CEO of Tempus.

“Putting cutting-edge technology into the hands of our physicians enhances the resources they need to best serve their patients,” Chi Van Dang, professor & director, Abramson Cancer Center.

Tempus enables physicians to deliver personalized cancer care through its interactive analytical and machine learning platform.The company provides genomic sequencing services and analyzes molecular and therapeutic data to empower physicians to make real-time, data-driven decisions.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login